版本:
中国

BRIEF-Intellia Therapeutics announces patent for CRISPR/CAS genome editing in China

June 19 Intellia Therapeutics Inc:

* Intellia Therapeutics announces patent for CRISPR/CAS genome editing in China

* Intellia Therapeutics Inc - patent includes claims covering methods for editing DNA in non-cellular and cellular settings

* Intellia Therapeutics - patent also includes CRISPR/CAS9 composition of matter and system claims for use in any setting

* Intellia Therapeutics Inc - SIPO has indicated it will grant a patent broadly covering CRISPR/CAS9 single-guide gene editing methods and compositions Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐